BioTransplant, Novartis Pharma AG deal

The companies will develop BTRN's ImmunoCognance mixed bone marrow chimerism technology, which creates immune tolerance to xenotransplantation.

Read the full 174 word article

How to gain access

Continue reading with a
two-week free trial.